State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China.
Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Adv Healthc Mater. 2023 Oct;12(27):e2300994. doi: 10.1002/adhm.202300994. Epub 2023 Jul 20.
Ferroptosis as programmed cell death received considerable attention in cancer research. Recently, studies have associated ferroptosis with photodynamic therapy (PDT) because PDT promotes glutathione (GSH) deletion, glutathione peroxidase 4 (GPX4) degradation, and lipid peroxide accumulation. However, PDT-induced ferroptosis may be potentially prevented by ferroptosis suppressor protein 1 (FSP1). To address this limitation, herein, a novel strategy is developed to trigger ferroptosis by PDT and FSP1 inhibition. For enhancement of this strategy, a photoresponsive nanocomplex, self-assembled by BODIPY-modified poly(amidoamine) (BMP), is utilized to stably encapsulate the inhibitor of FSP1 (iFSP1) and chlorin e6 (Ce6). The nanosystem promotes intracellular delivery, penetration, and accumulation of ferroptosis inducers in tumors with light irradiation. The nanosystem presents high-performance triggering of ferroptosis and immunogenic cell death (ICD) in vitro and in vivo. Importantly, the nanoparticles increase tumor infiltration of CD8 T cells and further enhance the efficacy of anti-PD-L1 immunotherapy. The study suggests the potential of photo-enhanced synergistic induction of ferroptosis by the photoresponsive nanocomplexes in cancer immunotherapy.
铁死亡作为一种程序性细胞死亡方式,在癌症研究中受到了广泛关注。最近的研究表明,铁死亡与光动力疗法(PDT)有关,因为 PDT 会促进谷胱甘肽(GSH)的缺失、谷胱甘肽过氧化物酶 4(GPX4)的降解和脂质过氧化物的积累。然而,PDT 诱导的铁死亡可能会被铁死亡抑制蛋白 1(FSP1)潜在地抑制。为了解决这一限制,本文提出了一种通过 PDT 和 FSP1 抑制来触发铁死亡的新策略。为了增强这种策略,利用由 BODIPY 修饰的聚(酰胺-胺)(BMP)自组装的光响应纳米复合物来稳定包封 FSP1 抑制剂(iFSP1)和氯乙酮 6(Ce6)。该纳米系统在光照下促进铁死亡诱导剂在肿瘤中的细胞内传递、渗透和积累。该纳米系统在体外和体内均表现出高效的铁死亡和免疫原性细胞死亡(ICD)触发作用。重要的是,这些纳米颗粒增加了肿瘤浸润的 CD8 T 细胞,并进一步增强了抗 PD-L1 免疫疗法的疗效。该研究表明,光响应纳米复合物在癌症免疫治疗中具有通过光增强协同诱导铁死亡的潜力。
Adv Healthc Mater. 2023-10
Nan Fang Yi Ke Da Xue Xue Bao. 2022-12-20
ACS Appl Mater Interfaces. 2021-6-23
Drug Deliv. 2025-12
Theranostics. 2025-4-13
Bioact Mater. 2024-11-5
J Nanobiotechnology. 2024-10-16
J Control Release. 2022-6
Mol Cancer. 2022-2-12
Cancer Commun (Lond). 2022-2
Nat Rev Cancer. 2022-3
J Control Release. 2022-1